Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Dr. Reddy's Laboratories Limited: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Dr. Reddy's Laboratories Limited
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses: Dr. Reddy's Laboratories Limited
  • The company's enterprise value to sales, at 2.87 times its current sales, is high.
  • The company is not the most generous with respect to shareholders' compensation.
  • Most analysts recommend that the stock should be sold or reduced.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Rating Financials

Dr. Reddy's Laboratories Limited SectorIndia

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Dr. Reddy's Laboratories Limited SectorIndia

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Dr. Reddy's Laboratories Limited SectorIndia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Dr. Reddy's Laboratories Limited SectorIndia

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Dr. Reddy's Laboratories Limited SectorIndia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
1.12TCr
BBB
1,01000Cr
A
58TCr
BBB
40TCr -
AA
- -
33TCr
AA
28TCr
AAA
28TCr
A
20TCr
A
19TCr
A
16TCr
AA
Average 34.4TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 500124 Stock
  4. Ratings Dr. Reddy's Laboratories Limited
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!